谁有关于介绍公司的简短口语话的英文吗？

ADImmune Corporation, otherwise called “Kuo Kwang Biotechnology Company”, formerly Kuo Kwang Serum and Vaccine Laboratories, was founded in 1965 through the technical support of the Kitasato Institute, one of the biggest developers and producers of vaccines in Japan. ADImmune is the only human vaccine manufacturer in Taiwan. Under strict cGMP regulations, ADImmune produces Japanese encephalitis vaccine (JEV) and tetanus toxoid. The former item commands 100% of the local market while the later occupied 50% of the market.

In 1997, ADImmune doubled its capital and brought in new management to meet with new financial, technical and regulatory needs. With several new candidates in the product pipeline, ADImmune is actively looking for advanced technologies in the development and production of biologics for disease prevention and treatment.

Since 1998, ADImmune received grants from the Ministry of Economic Affairs to develop new technology and products, including the new production process of JEV, using kidney cell line from African Green Monkey as a vehicle under a serum-free cell growth condition. The clinical trials are scheduled to begin in 2008. Another major program focused by the company is the platform technology of “DNA Vaccine”. ADImmune has established a collaboration program with the Developmental Center for Biotechnology and other research institues in Taiwan, to develop plasmid DNA manufacturing processes. In one of the projects that uses JEV DNA vaccine as a working model, preliminary mice studies have been completed with promising results. ADImmune believes that Japanese encephalitis being an East Asian epidemic receives little attention from mainstream pharmaceutical companies in the West. Therefore ADImmune stands a good chance of becoming a major supplier of superior quality JEV product worldwide.

Recently the Executive Yuan Development Fund, a major government investment program, has invested directly into ADImmune with NT$512 million (US$16 million) as a sign of support that is equal to approximately 21% of post-money stake. The money will be used to build up a state-of-the-art cGMP level manufacturing plant for vaccine production and plasmid DNA contract manufacturing business.

The Company has a factory in central Taiwan with over 10,000 square feet of GMP facilities at present. There are over 70 employees with advanced education and experience. Dr. Wenlii Lin, President and CEO, has a long credential in the vaccine business, held senior R&D and management position in Lederle Labs and other US companies.
国光生物科技股份有限公司，原名「国光血清疫苗制造股份有限公司」，成立於1965年，从事人用及动物用疫苗的制造及销售。国光生技公司在历届经理人稳健经营的领导下，本著以开发生产疫苗为职志，为维护人类健康而努力。
国光生技公司目前主要产品为流行性感冒疫苗、人用日本脑炎疫苗，破伤风疫苗及结核菌素等。其中日本脑炎的国内市场占有率为100%；该产品具有效性、安全性及稳定性，已在国内建立良好产品市场信誉，更重要的，对於政府的日本脑炎防疫政策，具有举足轻重的影响。另一产品破伤风疫苗，其制备的品质及纯度远高於欧美制品，台湾市占率已高达50%，流行性感冒疫苗市占率亦逐年成长。
今日的国光生技公司，拥有丰富的生产经验和完整的疫苗生产设备，为卫生署认可之cGMP级的生物制剂厂，并且为国内唯一的民营人用疫苗生产公司。除此之外，国光生技公司更长期与日本知名的疫苗研制单位－北里研究所合作，以期开拓更多、更有效的人用疫苗之产品，并提升疫苗生产技术。
国光生技公司，未来在产品方面将以进入亚洲市场为目标，对於基因或蛋白制剂将积极争取全球性代工业务，中短期以流行性感冒疫苗自制计划及日本脑炎无血清细胞培养制程为首要目标。